Award
NIH Reporter #5P01CA065493-29
"Off-the-Shelf" iPSC-Derived Regulatory T Cell Immunotherapeutics
Recipient
National Cancer Institute (NCI), part of the NIH
Award Amount
$595,443.00
Ceiling
$595,443.00
Awarded
July 28, 2026
Identifier
5P01CA065493-29
NIH awarded a grant to develop off-the-shelf iPSC-derived regulatory T cell immunotherapeutics targeting AML, managed by the National Cancer Institute.
Description
NIH grant opportunity for research in immunotherapy targeting acute myeloid leukemia (AML). The project involves developing off-the-shelf CAR T cell therapies using induced pluripotent stem cells. The award is managed by the National Cancer Institute. The project aims to study T cell development, genome editing, and immunotherapy strategies. Project duration is from May 1, 2026, to April 30, 2028.